公司資料
Lipocine Inc. 股價、新聞與催化劑
- 股票代碼:
- LPCN
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
2.05 USD (-2.84%)
收盤價
最後更新: 2026年8月17日
18.5M USD
市值
股價為何變動
As of Aug 17, 2026, LPCN closed down 2.84% at $2.05. No new same-company headline was identified in the current news window.
公司概覽
Oral Drug-Delivery Platform
Lipocine develops oral formulations intended to improve the delivery of therapeutics that are otherwise difficult to administer effectively by mouth.
LPCN 1154
LPCN 1154 is an oral formulation of brexanolone developed for postpartum depression. A Phase 3 study did not meet its primary endpoint, leaving the program's future development path uncertain.
Product-Focused Development Model
The company applies its formulation technology to established active pharmaceutical ingredients, seeking differentiated dosing, convenience or pharmacokinetic profiles in endocrine and neuropsychiatric indications.
未來催化劑
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。